<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza A virus is an RNA orthomyxovirus of approximately 13 kb in length, with an eight-segment genome. It is typically classified on the basis of hemagglutinin (HA) and neuraminidase (NA), of which there are 16 and 9 main variants, respectively (
 <xref rid="B1" ref-type="bibr">1</xref>). Genetic reassortment underpins the potential for transmission between different host species (
 <xref rid="B2" ref-type="bibr">2</xref>) and for the evolution of highly pathogenic variants (
 <xref rid="B3" ref-type="bibr">3</xref>
 <xref ref-type="bibr" rid="B4">–</xref>
 <xref rid="B6" ref-type="bibr">6</xref>), recognized in the WHO list of “ten threats to global health” (
 <xref rid="B7" ref-type="bibr">7</xref>). Seasonal influenza causes an estimated 650,000 deaths globally each year, and the H3N2 variant alone kills 35,000 people each year in the United States (
 <xref rid="B1" ref-type="bibr">1</xref>, 
 <xref rid="B8" ref-type="bibr">8</xref>). Certain groups are particularly at risk, including older adults, infants, young children, pregnant women, those with underlying lung disease, and the immunocompromised (
 <xref rid="B9" ref-type="bibr">9</xref>). The burden of disease disproportionately affects low-/middle-income settings (
 <xref rid="B10" ref-type="bibr">10</xref>). Influenza virus diagnostics and surveillance are fundamental to identify the emergence of novel strains, to improve the prediction of potential epidemics and pandemics (
 <xref rid="B4" ref-type="bibr">4</xref>, 
 <xref rid="B8" ref-type="bibr">8</xref>), and to inform vaccine strategy (
 <xref rid="B11" ref-type="bibr">11</xref>). Diagnostic data facilitate real-time surveillance, can underpin infection control interventions (
 <xref rid="B12" ref-type="bibr">12</xref>, 
 <xref rid="B13" ref-type="bibr">13</xref>), and can inform the prescription of neuraminidase inhibitors (NAI) (
 <xref rid="B9" ref-type="bibr">9</xref>).
</p>
